IO Frontiers World 2019


Christopher Heery

Dr Christopher Heery

Chief Medical Officer, Bavarian Nordic

Dr. Christopher Heery is the Chief Medical Officer for Bavarian Nordic where he oversees the clinical development of BN’s pipeline, comprising therapeutic cancer vaccines and vaccines for prevention of infectious diseases.  He is a medical oncologist by training. He trained at the National Cancer Institute in the Laboratory of Tumor Immunology and Biology, where he went on to be the Head of the Clinical Trials group in that translational ImmunoOncology-focused branch. He has personally run a wide variety of immunotherapy trials using a variety of first-in-human agents including therapeutic cancer vaccines, checkpoint inhibitors, antibody-cytokine conjugates, and cytokine targeting antibodies. His trial experience also includes combination strategies in IO and IO with standard therapies based on mechanistic rationale.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy